Revenue $162.473M
EBITDA -$148.19
Income -$166.43
Revenue Q/Q 62.79%
Revenue Y/Y 20.09%
P/E 0.00
Forward P/E N/A
EV/Sales 1.06
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 2.35
P/FCF N/A
Price/Book 2.22
Book/Share 0.04
Cash/Share 2.02
FCF yield -35.61%
Employees 270
RPE $601.752k
Volume 21.428M / 1.498M
Relative vol. 14.31 ×
EPS N/A
EPS Q/Q 41.67%
Est. EPS Q/Q -26.09%
Profit margin -102.44%
Oper. margin -100.07%
Gross margin 35.72%
EBIT margin -97.64%
EBITDA margin -91.21%
Ret. on assets -53.79%
Ret. on equity 5,286.46%
ROIC -36.43%
ROCE -80.46%
Volatility 36.11%
Beta 0.00
RSI 40.65
Range $0.10 – $0.14
52 weeks $0.04 – $5.18
SMA 50 $0 -10.59%
SMA 200 $0 -144.58%
1 year target $46 +43,271.32%
Mean Recomm. 1.83
Shares outst. 48.118M
Shares float 0.000 0.00%
Short % of float 13.20%
Short ratio 5.24

Recent Nanostring Technologies Inc news

Sunday, 4 February 2024
 
morningstar
NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology
Thursday, 1 February 2024
 
biospace
NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability
Sunday, 7 January 2024
 
morningstar
NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution
Thursday, 4 January 2024
 
businesswire
NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference
Thursday, 16 November 2023
 
yahoo
Here’s What Led Conestoga Capital Advisors to Sell Nanostring Technologies
Thursday, 14 September 2023
 
morningstar
NanoString to Host Virtual Spatial Genomics Summit September 19
Tuesday, 8 August 2023
 
businesswire
NanoString to Webcast Presentations from Upcoming Healthcare Conferences
Thursday, 3 August 2023
 
businesswire
NanoString Technologies Releases Operating Results for Second Quarter of 2023
Tuesday, 11 July 2023
 
morningstar
Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws
Friday, 30 June 2023
 
wallstreet-online.de
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
Thursday, 18 May 2023
 
fool
Why Shares of NanoString Technologies Are Falling Thursday
Wednesday, 12 April 2023
 
yahoo
Investors in NanoString Technologies have unfortunately lost 69% over the last year
Thursday, 2 February 2023
 
marketscreener
Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy
Thursday, 19 January 2023
 
yahoo
NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager
Sunday, 8 January 2023
 
businesswire
NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022
Saturday, 31 December 2022
 
insidermonkey
NanoString Technologies, Inc. Q3 2022 Earnings Call Transcript
Sunday, 13 November 2022
 
yahoo
Analyst Forecasts Just Became More Bearish On NanoString Technologies, Inc.
Thursday, 10 November 2022
 
businesswire
NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences
Monday, 11 July 2022
 
businesswire
NanoString to Release Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022
Wednesday, 18 May 2022
 
businesswire
NanoString to Webcast Presentation from the UBS 2022 Global Healthcare Conference
Wednesday, 27 April 2022
 
stockhouse
NanoString to Release First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022
Monday, 18 April 2022
 
duckduckgo
NanoString Appoints Dr. Teresa Foy to Board of Directors
Wednesday, 13 April 2022
 
marketwatch
NanoString stock plunges after revenue warning, but analyst says selloff appears 'way overdone'
Friday, 8 April 2022
 
stockhouse
NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research Conference
Thursday, 7 April 2022
 
businesswire
NanoString Launches New nCounter Pro Analysis System
Tuesday, 1 March 2022
 
yahoo
NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
Thursday, 24 February 2022
 
yahoo
NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference
duckduckgo
NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28
Tuesday, 8 February 2022
 
gurufocus
CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...
Monday, 10 January 2022
 
streetinsider
NanoString Reports Inducement Grant Under Nasdaq Listing Rules
Saturday, 11 December 2021
 
insidermonkey
Hedge Funds Are Piling Into NanoString Technologies Inc
Wednesday, 10 November 2021
 
fool
NanoString Technologies Inc Q3 2021 Earnings Call Transcript
Tuesday, 13 July 2021
 
yahoo
Hedge Funds Aren’t Crazy About NanoString Technologies Inc Anymore - Yahoo Finance
Thursday, 8 July 2021
 
yahoo
NanoString to Release Second Quarter 2021 Operating Results and Host Conference Call on Wednesday, August 4, 2021
Thursday, 27 May 2021
 
yahoo
NanoString to Webcast Presentation from the Jefferies Virtual Healthcare Conference
Thursday, 20 May 2021
 
yahoo
NanoString to Webcast Presentation from the UBS Global Healthcare Conference
Monday, 17 May 2021
 
yahoo
NanoString's GeoMx Mouse Whole Transcriptome Atlas Expands Leadership in Spatial Genomics by Enabling Genome-Wide RNA Profiling
Tuesday, 20 April 2021
 
yahoo
Is NSTG Stock A Buy or Sell?
Thursday, 8 April 2021
 
markets.businessinsider
NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research Conference
Tuesday, 6 April 2021
 
yahoo
NanoString to Release First Quarter 2021 Operating Results and Host Conference Call on Monday, May 10, 2021
Monday, 1 March 2021
 
yahoo
NanoString Technologies Reports Q4 Loss, Tops Revenue Estimates
yahoo
NanoString Technologies Releases Fourth Quarter and Full Year 2020 Operating Results and Provides 2021 Financial Outlook
yahoo
NanoString Launches Technology Access Program for the Spatial Molecular Imager Platform and Showcases Spatially Resolved Transcriptomic Research at 2021 Advances in Genome Biology and Technology Conference
Wednesday, 24 February 2021
 
yahoo
NanoString to Webcast Presentation from the 41st Annual Cowen Healthcare Conference
Monday, 22 February 2021
 
businesswire
NanoString Announces the Launch of the Whole Transcriptome Atlas with Data to be Presented at the Third Annual Spatial Genomics Summit on February 23, 2021
Sunday, 10 January 2021
 
yahoo
NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2020
Wednesday, 6 January 2021
 
yahoo
Nature Methods Selects Spatially-Resolved Transcriptomics as the Method of the Year for 2020
Friday, 18 December 2020
 
yahoo
Is NSTG A Good Stock To Buy Now?
8-K 28 May 2024 Material Modifications to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Ch...
8-K 22 May 2024 Regulation FD Disclosure; Financial Statements and Exhibits
8-K 8 May 2024 Material Modifications to Rights of Security Holders
8-K 6 May 2024 Completion of Acquisition or Disposition of Assets; Departure of Directors or Certain Officers; Election of...
8-K 22 Apr 2024 Regulation FD Disclosure; Financial Statements and Exhibits
8-K 19 Apr 2024 Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Other Events; F...
8-K 22 Mar 2024 Regulation FD Disclosure; Financial Statements and Exhibits
8-K 12 Mar 2024 Entry into a Material Definitive Agreement; Other Events
8-K 13 Feb 2024 Bankruptcy or Receivership; Financial Statements and Exhibits
8-K 8 Feb 2024 Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation unde...
8-K 5 Feb 2024 Bankruptcy or Receivership; Triggering Events That Accelerate or Increase a Direct Financial Obligation or ...
Insider
Trans.
Transaction
Price per share Total value
Joseph M Beechem SVP, Research, and Development Option 6 May 2024 $0.19 $28,092
K Thomas Bailey Chief Financial Officer Option 6 May 2024 $0.19 $34,713
Janet George Director Option 6 May 2024 $0.19 $7,815
Dana E. Rollison Director Option 6 May 2024 $0.19 $7,815
Teresa M. Foy Director Option 6 May 2024 $0.19 $8,545
Gregory Norden Director Option 6 May 2024 $0.19 $7,815
Jonathan Todd Garland Chief Commercial Officer Option 6 May 2024 $0.19 $38,000
Charles P Jr Waite Director Option 6 May 2024 $0.19 $7,815
R Bradley Gray President and CEO Option 6 May 2024 $0.19 $117,274
Kirk Malloy Director Option 6 May 2024 $0.19 $7,815
William Young Director Option 6 May 2024 $0.19 $7,815
Q3 2021
10 November 2021
Q3 2021 Earnings Call Transcript
Q1 2020
9 May 2020
Q1 2020 Earnings Call Transcript
Q3 2019
5 November 2019
Q3 2019 Earnings Call Transcript
Q2 2019
1 August 2019
Q2 2019 Earnings Call Transcript
Q2 2019
31 July 2019
CEO Brad Gray on Q2 2019 Results - Earnings Call Transcript
Q1 2019
10 May 2019
CEO Brad Gray on Q1 2019 Results - Earnings Call Transcript
Q1 2019
10 May 2019
Q1 2019 Earnings Call Transcript
Q4 2018
7 March 2019
CEO Brad Gray on Q4 2018 Results - Earnings Call Transcript
Q4 2018
7 March 2019
Q4 2018 Earnings Conference Call Transcript
Q3 2018
10 November 2018
CEO Brad Gray on Q3 2018 Results - Earnings Call Transcript
Q2 2018
8 August 2018
CEO Brad Gray on Q2 2018 Results - Earnings Call Transcript

513 people own Nanostring Technologies Inc on Robinhood

Powered by Robintrack.

Overall analyst rating

Price target

Current $0.11
Average $45.67
Low $43 High $52

Nanostring Technologies Inc executives

Insider Age Since Compensation
R. Bradley Gray (43) President, Chief Executive Officer, and Director since 2010 43 2010 $7,288,840
K. Thomas Bailey (51) Chief Financial Officer since 2018 51 2018 $2,108,690
Joseph Beechem (62) Senior Vice President - Research and Development since 2012 62 2012 $2,094,840
John Brown (62) Senior Vice President - Sales and Marketing since 2017 62 2017 $2,092,500
David Ghesquiere (53) Senior Vice President - Corporate and Business Development since 2013 53 2013 $1,455,550
R. Bradley Gray (44) CEO, Pres, and Director 44 $1,141,130
K. Thomas Bailey M.B.A. (52) Chief Financial Officer 52 $638,164
Dr. Joseph M. Beechem (63) Chief Scientific Officer, Sr. VP of R, and Director 63 $615,920
J. Chad Brown (63) Sr. VP of Sales and Marketing 63 $612,994
David W. Ghesquiere (54) Sr. VP of Corp. and Bus. Devel. 54 $598,612
William Young (75) Independent Chairman of the Board since 2010 75 2010 $241,462
Gregory Norden (62) Independent Director since 2012 62 2012 $212,251
Don Kania (65) Independent Director since 2019 65 2019 $208,100
Charles Waite (64) Independent Director since 2004 64 2004 $207,479
Elisha Finney (58) Independent Director since 2017 58 2017 $207,201
Kirk Malloy (53) Independent Director since 2016 53 2016 $195,979
Robert Hershberg (57) Independent Director since 2015 57 2015 $194,979
Elizabeth Schneider Ph.D.
Dr. Philippa Webster Ph.D.
Dr. Mary Tedd Allen (58) Sr. VP of Strategic Initiatives 58
Kathryn Surace-Smith (62) Sr. VP of HR, Legal Affairs, and Corp. Sec. 62
Douglas S. Farrell
Mark A. Winham
Company Market cap P/E EV/EBITDA P/S P/B P/FCF Change
$381.19M 0.00 N/A 2.35 2.22 N/A -37.43%
$210.98B 36.37 23.69 4.97 4.51 27.60 +0.21%
$45.56B 31.74 29.12 6.91 7.79 29.62 +2.33%
$33.03B N/A N/A 7.35 5.75 90.25 -0.89%
$12.46B N/A 15.07 4.78 1.43 67.09 -2.29%
$2.10B N/A N/A 10.49 3.00 N/A -1.50%

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

  • Health Care > Biotechnology
  • Nanostring Technologies Inc, 530 Fairview Avenue North, Seattle 98109, United States
  • 206 378 6266
  • Investor relations

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

(in millions USD) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Current assets
Cash $94.098 $114.93 $122.033 $113.148
Short term investments $3.299 $3.297 $33.236 $84.282
Net receivables $48.352 $42.982 $34.867 $31.506
Inventory $55.159 $48.849 $46.711 $43.273
Total current assets $211.807 $221.445 $251.858 $286.774
Long term investments
Property, plant & equipment $59.411 $63.397 $64.213 $62.038
Goodwill & intangible assets
Total noncurrent assets $62.906 $67.545 $68.557 $66.638
Total investments $3.299 $3.297 $33.236 $84.282
Total assets $274.713 $288.99 $320.415 $353.412
Current liabilities
Accounts payable $33.335 $20.868 $20.486 $16.619
Deferred revenue $18.471 $17.123 $16.246 $13.342
Short long term debt $5.578 $5.44 $5.333 $5.518
Total current liabilities $77.532 $62.433 $57.991 $58.86
Long term debt $242.124 $243.182 $244.204 $244.984
Total noncurrent liabilities $247.747 $248.018 $248.804 $248.738
Total debt $247.702 $248.622 $249.537 $250.502
Total liabilities $325.279 $310.451 $306.795 $307.598
Stockholders' equity
Retained earnings -$931.613 -$894.202 -$850.534 -$809.296
Other stockholder equity $0.004 $0.004 -$0.055 -$0.589
Total stockholder equity -$50.566 -$21.461 $13.62 $45.814
(in millions USD) 2022 2021 2020
Current assets
Cash $113.148 $107.068 $411.848
Short term investments $84.282 $241.821 $28.883
Net receivables $31.506 $40.13 $31.1
Inventory $43.273 $31.486 $22.959
Total current assets $286.774 $427.62 $498.98
Long term investments
Property, plant & equipment $62.038 $46.269 $42.32
Goodwill & intangible assets
Total noncurrent assets $66.638 $51.861 $45.215
Total investments $84.282 $241.821 $28.883
Total assets $353.412 $479.481 $544.195
Current liabilities
Accounts payable $16.619 $14.283 $5.313
Deferred revenue $13.342 $11.001 $7.453
Short long term debt $5.518 $4.889 $4.313
Total current liabilities $58.86 $52.155 $37.099
Long term debt $244.984 $246.837 $198.305
Total noncurrent liabilities $248.738 $250.364 $200.148
Total debt $250.502 $251.726 $202.618
Total liabilities $307.598 $302.519 $237.247
Stockholders' equity
Retained earnings -$809.296 -$649.753 -$542.03
Other stockholder equity -$0.589 -$0.318 $0.083
Total stockholder equity $45.814 $176.962 $306.948

Income statement

(in millions USD) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $48.089 $44.157 $35.805 $34.422
Cost of revenue $30.686 $29.757 $22.871 $21.122
Gross profit $17.403 $14.4 $12.934 $13.3
Operating activities
Research & development $17.115 $18.214 $16.118 $19.086
Selling, general & administrative $36.755 $39.076 $37.366 $36.895
Total operating expenses $53.87 $57.29 $53.484 $55.981
Operating income -$36.467 -$42.89 -$40.55 -$42.681
Income from continuing operations
EBIT -$35.563 -$41.574 -$39.272 -$42.234
Income tax expense -$0.049 $0.205 $0.075 -$0.005
Interest expense $1.897 $1.889 $1.891 $1.885
Net income
Net income -$37.411 -$43.668 -$41.238 -$44.114
Income (for common shares) -$37.411 -$43.668 -$41.238 -$44.114
(in millions USD) 2022 2021 2020
Revenue
Total revenue $127.262 $145.085 $117.316
Cost of revenue $65.475 $68.304 $52.409
Gross profit $61.787 $76.781 $64.907
Operating activities
Research & development $70.841 $69.504 $62.857
Selling, general & administrative $143.129 $115.503 $90.097
Total operating expenses $213.97 $185.007 $152.954
Operating income -$152.183 -$108.226 -$88.047
Income from continuing operations
EBIT -$151.691 -$107.597 -$94.417
Income tax expense $0.317 $0.167 $0.253
Interest expense $7.535 $7.49 $15.408
Net income
Net income -$159.543 -$115.254 -$110.078
Income (for common shares) -$159.543 -$115.254 -$110.078
(in millions USD) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$37.411 -$43.668 -$41.238 -$44.114
Operating activities
Depreciation $5.074 $5.006 $4.643 $4.042
Business acquisitions & disposals
Stock-based compensation $7.44 $8.436 $7.626 $6.264
Total cash flows from operations -$19.699 -$31.448 -$35.749 -$28.081
Investing activities
Capital expenditures -$1.916 -$5.692 -$7.678 -$5.476
Investments $30 $51.476 $29.589
Total cash flows from investing -$1.916 $24.308 $43.798 $24.113
Financing activities
Dividends paid
Sale and purchase of stock $0.866 $0.092 $1.374 $0.023
Net borrowings -$0.044 -$0.056 -$0.07 -$0.076
Total cash flows from financing $0.822 $0.036 $0.814 -$0.053
Effect of exchange rate -$0.039 $0.001 $0.022 $0.1
Change in cash and equivalents -$20.832 -$7.103 $8.885 -$3.921
(in millions USD) 2022 2021 2020
Net income -$159.543 -$115.254 -$110.078
Operating activities
Depreciation $12.205 $9.321 $8.976
Business acquisitions & disposals
Stock-based compensation $25.908 $30.173 $19.374
Total cash flows from operations -$128.606 -$90.549 -$81.662
Investing activities
Capital expenditures -$23.066 -$8.647 -$7.457
Investments $155.563 -$211.575 $98.698
Total cash flows from investing $132.497 -$220.222 $91.241
Financing activities
Dividends paid
Sale and purchase of stock $4.109 $8.879 $237.443
Net borrowings -$0.333 -$0.236 $145.02
Total cash flows from financing $2.272 $6.058 $373.048
Effect of exchange rate -$0.083 -$0.067 $0.188
Change in cash and equivalents $6.08 -$304.78 $382.627

Recent institutional transactions

Quarter Shareholder Change
Shares owned
Shares
Value (in thousands USD)
2024 Q1 Goldman Sachs Group Inc
-97.28%
21,525 $1,722
2024 Q1 Barclays PLC
-97.28%
1,994 $0
2024 Q1 Simplex Trading
-99.38%
200 $0
2024 Q1 Cadence Wealth Management
+120.67%
41,903 $3,352
2024 Q1 Shell Asset Management Co
-10.04%
1,264 $0
2023 Q4 Polar Capital PLC
Sold out
3,975,000 $2,974,890
2023 Q4 Blackrock
Sold out
3,574,938 $2,675,482
2023 Q4 Morgan Stanley
Sold out
2,333,231 $1,746,190
2023 Q4 State Street Corp
Sold out
1,536,756 $1,150,108
2023 Q4 Gsa Capital Partners LL.P.
Sold out
1,279,363 $957

Institutional shareholders

Shareholder Stake
Shares owned
Shares
Value (in thousands USD)
Clarus Ventures 8.39% 4,036,025
Polar Capital PLC 8.26% 3,975,000
Blackrock 7.43% 3,574,938
Vanguard Group Inc 7.42% 3,569,859
Fred Alger Management 5.22% 2,511,364
Morgan Stanley 4.85% 2,333,231
D. E. Shaw & Co 4.41% 2,120,143
Acadian Asset Management 4.16% 2,003,708
Prosight Management, L.P. 4.16% 2,000,000
State Street Corp 3.19% 1,536,756